The Cataract pipeline report provides detailed information of the Cataract pipeline products from the initial phase of product development until its commercialisation in the Cataract market.

Cataract Pipeline Insight | Cataract Pipeline Assessment, Pipeline Drugs

DelveInsight&rsquo;s, &ldquo;Cataract- Pipeline Insight, 2025&rdquo; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cataract pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>Cataract: Understanding</h2>
Cataract: Overview
Cataracts are when the lens of the eye becomes cloudy.&nbsp; This restricts the amount of light that reaches the retina and affects vision. Cataracts tend to develop slowly over a period of years. In the early stages it may not produce any symptoms. However, without treatment (normally surgery) cataracts will get worse and eventually lead to complete blindness. In New Zealand, cataracts are a leading cause of vision loss in older adults. The most common cause of cataracts is ageing, while other causes include other medical conditions, eye injuries, genetic defects and reaction to some medications. Cataracts are a natural part of ageing and are common in people over 60 years old.&nbsp; Most elderly people with cataracts have no other contributing health conditions or eye diseases. Cataracts can also exist at birth (congenital cataracts) due to a faulty gene, and can develop in children (childhood cataracts) associated with infection or trauma during pregnancy. Cataracts in new-borns and children are rare. Signs and symptoms of cataracts can include: Cloudy, blurry, fuzzy, foggy, or filmy vision, a noticeable cloudiness in the pupil, sensitivity to light or glare from lights, eg: from headlights when driving at night .A decrease in distance vision but an improvement in near vision, double vision (diplopia) or halos around lights ,frequent changes in eye prescriptions and many others. If cataracts are suspected, a referral to an eye specialist (ophthalmologist) is usually recommended. The eye specialist may carry out more detailed examinations of the eye and vision in order to determine the exact location and extent of the cataracts. Cataracts can be classified according to which part of the lens they affect. The location and extent of the cataract also determines the extent of the vision impairment. For example, vision may be significantly impaired if the centre of the lens is affected (nuclear cataracts); however, if the edges of the lens are affected (cortical cataracts) vision impairment may be barely noticeable. The symptoms of early cataracts may be improved with new prescription glasses and stronger lighting. However, once cataracts progress to the point that impaired vision reduces the person&rsquo;s quality of life and interferes with daily activities, surgery is the only effective treatment. Cataract surgery is most commonly performed as a day-stay procedure and is usually carried out under a local anaesthetic with mild sedation.
&nbsp;
"Cataract- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cataract pipeline landscape is provided which includes the disease overview and Cataract treatment guidelines. The assessment part of the report embraces, in depth Cataract commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cataract collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
<h2>Report Highlights</h2>
The companies and academics are working to assess challenges and seek opportunities that could influence Cataract R&amp;D. The therapies under development are focused on novel approaches to treat/improve Cataract.
<h2>Cataract Emerging Drugs Chapters</h2>
This segment of the Cataract report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
Cataract Emerging Drugs
&nbsp;
NPI 002: Nacuity Pharmaceuticals
Nacuity has developed a prototype intravitreal implant loaded with a small antioxidant molecule, NPI-002, to slow cataract progression plus a proprietary injector. Nacuity has completed non-clinical testing, has received HREC approval for and expects to initiate a Phase 1/2 clinical study in Australia of NPI-002 during the fourth quarter of 2021.
&nbsp;
CGT 1507: CGeneTech
CGT 1507, is a small molecule which targets the Proteolytic enzyme. Currently, the drug is being developed in the Pre-Clinical stage of clinical trial evaluation for the treatment of Cataracts.
&nbsp;
Research programme: ocular therapeutics: Plex Pharmaceuticals
Research programme: ocular therapeutics (CAP 1160), is a small molecule that targets the HSP27 heat-shock protein modulators. Plex is developing this molecule, so that it can interact with AC and increase its CLA to reverse, slow and/or prevent the formation of cataracts. Alpha-crystallin (AC) is one of the three major eye lens crystallins and is a representative member of the small heat shock protein (sHsp) family. AC serves as molecular chaperone, protecting damaged or aged lens proteins and enzymes from aggregation that would otherwise lead to light scattering and cataract formation. It is well established that chaperone-like activity (CLA) of AC is critical for lens transparency and it is hypothesized that maintaining optimal or increasing chaperone activity might aid in the prevention or slowing of cataract.
Further product details are provided in the report&hellip;&hellip;..
<h2>Cataract: Therapeutic Assessment</h2>
This segment of the report provides insights about the different Cataract drugs segregated based on following parameters that define the scope of the report, such as:
&nbsp;
Major Players in Cataract
There are approx. 5+ key companies which are developing the therapies for Cataract. The companies which have their Cataract drug candidates in the most advanced stage, i.e. phase I /II include, Nacuity Pharmaceuticals.
&nbsp;
Phases
DelveInsight&rsquo;s report covers around 5+ products under different phases of clinical development like
<ul>
<li>Late stage products (Phase III)</li>
<li>Mid-stage products (Phase II)</li>
<li>Early-stage product (Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
</ul>
&nbsp;
Route of Administration
Cataract pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
<ul>
<li>Intra-articular</li>
<li>Intraocular</li>
<li>Intrathecal</li>
<li>Intravenous</li>
<li>Ophthalmic</li>
<li>Oral</li>
<li>Parenteral</li>
<li>Subcutaneous</li>
<li>Topical</li>
<li>Transdermal</li>
</ul>
&nbsp;
Molecule Type
Products have been categorized under various Molecule types such as
<ul>
<li>Oligonucleotide</li>
<li>Peptide</li>
<li>Small molecule</li>
</ul>
&nbsp;
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>Cataract: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cataract therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cataract drugs.
<h2>Cataract Report Insights</h2>
<ul>
<li>Cataract Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>Cataract Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Treatment Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Cataract drugs?</li>
<li>How many Cataract drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cataract?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Cataract therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Cataract and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>

Introduction
Executive Summary
Cataract: Overview
<ul>
<li>Causes</li>
<li>Mechanism of Action</li>
<li>Signs and Symptoms</li>
<li>Diagnosis</li>
<li>Disease Management</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type</li>
</ul>
Cataract&ndash; DelveInsight&rsquo;s Analytical Perspective
Late Stage Products (Phase III)
<ul>
<li>Comparative Analysis</li>
</ul>
Drug name : Company name
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase I/ II)
<ul>
<li>Comparative Analysis</li>
</ul>
NPI 002: Nacuity Pharmaceuticals
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I)
<ul>
<li>Comparative Analysis</li>
</ul>
Drug name : Company name
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Preclinical and Discovery Stage Products
<ul>
<li>Comparative Analysis</li>
</ul>
CGT 1507: CGeneTech
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Cataract Key Companies
Cataract Key Products
Cataract- Unmet Needs
Cataract- Market Drivers and Barriers
Cataract- Future Perspectives and Conclusion
Cataract Analyst Views
Cataract Key Companies
Appendix

DelveInsight’s, “Cataract- Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cataract pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Cataract - Pipeline Insight, 2025

Cataract Pipeline Insights, 2025 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cataract market.